Industry Could Be Made To Pay For Stronger HTA Cooperation in EU
The European Commission wants to strengthen EU cooperation in the area of health technology assessment. Among the options it is considering are mandatory and voluntary participation models… and charging drug companies fees.
You may also be interested in...
Europe’s EUnetHTA collaboration is working on producing a raft of new joint HTA reports for medical device and drug developers, and it is planning to facilitate 35 early dialogues between HTA bodies and manufacturers. It is also exploring why only a few European countries are making full use of the reports it has produced so far. Meanwhile, the European Commission is gearing up to consult extensively on how to create a sustainable network for HTAs across Europe.
A proposal by the UK's HTA body NICE to charge companies for technology appraisals has raised several issues, such as the need for reforms to the HTA process, ensuring independence and credibility of appraisals, greater accountability and transparency at NICE, and the impact of fees on bringing new medicines to market.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.